DE69834179D1 - Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. - Google Patents

Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.

Info

Publication number
DE69834179D1
DE69834179D1 DE69834179T DE69834179T DE69834179D1 DE 69834179 D1 DE69834179 D1 DE 69834179D1 DE 69834179 T DE69834179 T DE 69834179T DE 69834179 T DE69834179 T DE 69834179T DE 69834179 D1 DE69834179 D1 DE 69834179D1
Authority
DE
Germany
Prior art keywords
chemokino
express
soluble
binding protein
encoding gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69834179T
Other languages
English (en)
Other versions
DE69834179T2 (de
Inventor
Geoffrey Smith
Aylwin Ng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxxon Therapeutics Ltd
Original Assignee
Oxxon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9703592.7A external-priority patent/GB9703592D0/en
Priority claimed from GBGB9800113.4A external-priority patent/GB9800113D0/en
Application filed by Oxxon Therapeutics Ltd filed Critical Oxxon Therapeutics Ltd
Publication of DE69834179D1 publication Critical patent/DE69834179D1/de
Application granted granted Critical
Publication of DE69834179T2 publication Critical patent/DE69834179T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69834179T 1997-02-21 1998-02-23 Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann. Expired - Fee Related DE69834179T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9703592 1997-02-21
GBGB9703592.7A GB9703592D0 (en) 1997-02-21 1997-02-21 Poxvirus chemokine-binding protein
GB9800113 1998-01-05
GBGB9800113.4A GB9800113D0 (en) 1998-01-05 1998-01-05 A soluble vaccinia virus protein that binds chemokines
PCT/GB1998/000569 WO1998037217A1 (en) 1997-02-21 1998-02-23 A soluble vaccinia virus protein that binds chemokines

Publications (2)

Publication Number Publication Date
DE69834179D1 true DE69834179D1 (de) 2006-05-24
DE69834179T2 DE69834179T2 (de) 2007-02-01

Family

ID=26311039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69834179T Expired - Fee Related DE69834179T2 (de) 1997-02-21 1998-02-23 Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.

Country Status (7)

Country Link
US (3) US6355252B1 (de)
EP (2) EP0985046B1 (de)
JP (1) JP4191255B2 (de)
AT (1) ATE323170T1 (de)
AU (1) AU749921B2 (de)
DE (1) DE69834179T2 (de)
WO (1) WO1998037217A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE323170T1 (de) * 1997-02-21 2006-04-15 Oxxon Therapeutics Ltd Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
WO2002080948A1 (en) * 2001-04-05 2002-10-17 The Trustees Of Princeton University Compositions and methods for treating inflammation and related conditions
US6852486B2 (en) 2001-07-12 2005-02-08 Immunex Corp. Viral proteins capable of binding LAR
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2003024404A2 (en) * 2001-09-20 2003-03-27 Schering Corporation Chemokines as adjuvants of immune response
WO2004005892A2 (en) * 2002-07-10 2004-01-15 The Regents Of The University Of California Antimicrobial activity of interferon-inducible elr chemokines
EP1578396A4 (de) * 2002-08-12 2007-01-17 David Kirn Verfahren und zusammensetzungen gegen pockenviren und krebs
US20100189747A1 (en) * 2003-07-31 2010-07-29 Raymond Weinstein Compositions and methods for treating or preventing hiv infection
US20050175627A1 (en) * 2003-09-24 2005-08-11 Oxxon Therapeutics Ltd. HIV pharmaccines
US20070160571A1 (en) * 2006-01-11 2007-07-12 Mitchell Krathwohl Composition and method for inducing protective vaccine response
WO2006076383A2 (en) * 2005-01-11 2006-07-20 Rosetta Stone Labs, Llc Composition and method for inducing a protective vaccine response
KR101772375B1 (ko) * 2005-09-07 2017-08-29 신라젠(주) Ｇｍ-ｃｓｆ를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
JP2009510102A (ja) * 2005-09-29 2009-03-12 ヴァイラル ロジック システムズ テクノロジー コーポレーション 免疫調節組成物およびその使用
US8293500B2 (en) 2006-03-22 2012-10-23 Viral Logic Systems Technology Corp. Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
KR20080084528A (ko) * 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
ES2456963T3 (es) 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
WO2009082594A2 (en) * 2007-11-26 2009-07-02 Fox Chase Cancer Center Secreted/cell bound poxvirus proteins and methods of use thereof as vaccines and anti-viral agents
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
ES2848650T3 (es) 2009-09-14 2021-08-11 Sillajen Biotherapeutics Inc Terapia combinada contra el cáncer con virus vaccinia oncolítico
BR112013017096A2 (pt) 2011-01-04 2020-09-01 Jennerex Inc. composição e métodos de indução de resposta citotóxica dependente de complemento mediado por anticorpo específico de tumor em animal tendo tumor, de geração de anticorpos in vivo, de inibição do crescimento ou morte de célula de câncer, para tratar indivíduo com câncer, para adaptar de terapia de câncer para indivíduo com câncer e para identificar antígeno específico de tumor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2202452T3 (es) 1995-04-19 2004-04-01 Viron Therapeutics, Inc. Proteina de union a quimiocinas y metodos de uso para la misma.
US6140064A (en) 1996-09-10 2000-10-31 Theodor-Kocher Institute Method of detecting or identifying ligands, inhibitors or promoters of CXC chemokine receptor 3
ATE323170T1 (de) * 1997-02-21 2006-04-15 Oxxon Therapeutics Ltd Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.
WO1998036766A1 (en) * 1997-02-21 1998-08-27 Isis Innovation Limited Anti-hiv protein
JP2001168323A (ja) * 1999-12-06 2001-06-22 Mitsubishi Electric Corp 半導体装置の製造方法

Also Published As

Publication number Publication date
JP2001513629A (ja) 2001-09-04
US20020071849A1 (en) 2002-06-13
EP0985046B1 (de) 2006-04-12
US6355252B1 (en) 2002-03-12
EP0985046A1 (de) 2000-03-15
JP4191255B2 (ja) 2008-12-03
EP1405916A1 (de) 2004-04-07
DE69834179T2 (de) 2007-02-01
ATE323170T1 (de) 2006-04-15
US20040142002A1 (en) 2004-07-22
AU749921B2 (en) 2002-07-04
WO1998037217A1 (en) 1998-08-27
AU6302098A (en) 1998-09-09
US7384643B2 (en) 2008-06-10

Similar Documents

Publication Publication Date Title
DE69834179D1 (de) Rekombinantes pockenvirus das das lösliche chemokine-bindende protein kodierende gen a41l nicht exprimieren kann.
FR2712603B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
ATE328068T1 (de) Papillomavirus vakzine
FR2716893B1 (fr) Virus recombinants, leur préparation et leur utilisation thérapeutique.
BR9405507A (pt) Adenovirus recombinante defeituoso linhagem celular e composição farmaceutica
EP1005376A4 (de) Methoden und zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
FI961755A (fi) Yhdistelmäadenovirusvektori ja menetelmiä sen käyttämiseksi
DE69032679D1 (de) Threo (2R, 3S)-3-amino-2-hydroxypentansäure und threo (2R,3S)-3-(p-methoxy-benzyloxycarbonyl/FMOC) amino-2-hydroxy-pentansäure
PT836648E (pt) Virus mva recombinante e sua utilizacao
NZ219909A (en) Recombinant vaccinia virus expressing human (hiv) retrovirus gene
DK1775346T3 (da) Disulfid-tværbundne glycoproteinhormonanaloger, deres fremstilling og anvendelse
BR9607583B1 (pt) plasmìdios procarióticos recombinantes.
ATE189701T1 (de) Impfstoffe gegen actinobacillus pleuropneumonie
DK476688D0 (da) Hiv-proteiner og -peptider, der er nyttige ved aids-diagnose, -profylakse og -terapi
AU4089899A (en) Stable envelope proteins for retroviral, viral and liposome vectors and use in gene and drug therapy
FR2724945B1 (fr) Vecteurs viraux et utilisation en therapie genique
WO1999020760A3 (en) Herg family potassium ion channel genes and protein
AU6292694A (en) Novel polypeptide, dna coding for said polypeptide, recombinant vector containing said dna, recombinant virus prepared using said vector, and use thereof
DK575787A (da) Rekombinant hcmv-afledt plasmid, dets fremstilling og anvendelse
FI971377A (fi) Adenovirusperäisiä virusvektoreita, joissa on kaksi terapeuttista geeniä: itsemurha- ja immuunistimuloiva geeni
AU2176997A (en) Novel fused protein, gene therefor, recombinant vector, recombinant virus, and its use
DK2385124T3 (da) Peptider, eller peptid-analoger, til modulering af bindingen af et PDZ protein og et PL protein
NZ219192A (en) Peptides related to p97 melanoma-associated peptide, recombinant virus and vaccines
AU6679498A (en) A novel bak binding protein, dna encoding the protein, and methods of use thereof
IE870898L (en) Recombinant vaccinia virus.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee